I
1.17
-0.01 (-1.27%)
| Previous Close | 1.18 |
| Volume | 98,008 |
| Price / Sales | 5.22 |
| Price / Book | 1.09 |
| 52 Weeks Range |
| Operating Margin (TTM) | -41,252.01% |
| Diluted EPS (TTM) | -0.870 |
| Quarterly Revenue Growth (YOY) | 103.60% |
| Total Debt/Equity (MRQ) | 1.00% |
| Current Ratio (MRQ) | 5.28 |
| Operating Cash Flow (TTM) | -47.70 M |
| Levered Free Cash Flow (TTM) | 34.37 M |
| Return on Assets (TTM) | -34.47% |
| Return on Equity (TTM) | -54.13% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | InflaRx N.V. | Mixed | Mixed |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| IFRX | - | - | - | 1.09 |
| SONN | 33 M | - | - | 2.07 |
| CDIO | - | - | - | 0.740 |
| REPL | - | - | - | 10.78 |
| INDP | - | - | - | 33.86 |
| ADXN | - | - | - | 1.30 |
AIStockmoo Score
| Value 35% | 0.0 |
| AI Insight info | NA |
| Relative Valuation info | NA |
| Financial Health info | 2.0 |
| Timing 35% | -0.9 |
| AI Technical info | NA |
| Technical Oscillators info | -2.5 |
| Technical Moving Averages info | 1.5 |
| Smart Money 30% | 0.0 |
| Analyst Consensus info | 0.0 |
| Insider Activity info | NA |
| News Mood info | NA |
| Environment | ×1.21 |
| Macro Environment info | -3.3 |
| Sector vs Market (6M) | -23.9% |
| Pillar Agreement | ×1.00 |
| Not in score | |
| Price Volatility info | -0.2 |
| Final Score | -0.38 |
Select this tab to load the latest available analysis.
|
InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 6.44% |
| % Held by Institutions | 26.24% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Montanova Capital, Llc | 30 Jun 2026 | 22,933,910 |
| Tcg Crossover Management, Llc | 30 Jun 2026 | 14,500,000 |
| Commodore Capital Lp | 30 Jun 2026 | 7,300,000 |
| Spruce Street Capital Lp | 30 Jun 2026 | 5,352,198 |
| 683 Capital Management, Llc | 30 Jun 2026 | 5,065,000 |
| Farallon Capital Management, L.L.C. | 30 Jun 2026 | 3,325,000 |
| Great Point Partners I Lp | 30 Jun 2026 | 3,046,557 |
| Adar1 Capital Management, Llc | 30 Jun 2026 | 3,000,000 |
| Kalehua Capital Management Llc | 30 Jun 2026 | 2,897,769 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 12 Nov 2026 | Yahoo Finance |
Down 20.3% in 4 Weeks, Here's Why You Should You Buy the Dip in InflaRx (IFRX)
The heavy selling pressure might have exhausted for InflaRx (IFRX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. |
| 06 Nov 2026 | Yahoo Finance |
InflaRx Announces Publication of Phase 1 Data Demonstrating Favorable Safety and Pharmacokinetic/Pharmacodynamic Profile of Izicopan
Izicopan achieved rapid and sustained inhibition of C5a/C5aR1 signalingPharmacokinetic results demonstrated dose-dependent exposure, with izicopan well tolerated across all single and multiple doses evaluatedFindings support Phase 2 development of izicopan in immune-inflammatory diseases Jena… |
| 03 Nov 2026 | Yahoo Finance |
InflaRx Highlights Izicopan Development Path and Commercial Opportunity in ANCA-Associated Vasculitis at Capital Markets Day
With a goal of providing multiple data sets demonstrating differentiated efficacy and safety in multiple ANCA-associated vasculitis (AAV) settings, InflaRx intends to begin two Phase 2 trials in 2027, with first data readout anticipated in 2028Phase 2 AAV izicopan program expected to include a… |
| 03 Nov 2026 | Yahoo Finance |
InflaRx Targets Kidney Protection, Steroid Reduction in AAV With Izicopan Trials
InflaRx (NASDAQ:IFRX) outlined plans to advance its oral C5a receptor antagonist izicopan in ANCA-associated vasculitis (AAV), with an initial focus on patients with kidney involvement and a parallel study intended to evaluate corticosteroid reduction. During the company’s capital markets event, Ch… |
| 27 Oct 2026 | Yahoo Finance |
InflaRx Announces November Investor Events
Jena, Germany, Oct. 27, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced its events calendar for November. Guggenheim Securities 3rd Annual Healthcare Innovation… |
| 22 Oct 2026 | Yahoo Finance |
InflaRx Highlights Izicopan’s Therapeutic Potential at Kidney Week 2026
Data from pre-clinical renal disease models demonstrate potential of izicopan for kidney protectionStructural modeling provides new insight into izicopan’s differentiated molecular profile Jena, Germany, Oct. 22, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company… |
| 02 Oct 2026 | Yahoo Finance |
InflaRx to Present Late-Breaking Pre-clinical Data on Izicopan at Kidney Week 2026
Jena, Germany, Oct. 02, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company has been selected for a late-breaking poster session at the American Society of… |
| 01 Oct 2026 | Yahoo Finance |
InflaRx Appoints Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development
Jena, Germany, Oct. 01, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced the appointment of Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical… |
| 21 Sep 2026 | Yahoo Finance |
InflaRx to Host Virtual Capital Markets Day
Event to be hosted on November 3, 2026 at 8:00 AM ESTFeatured speakers will include Peter A. Merkel, MD, MPH and Prof. Dr. Jörg Köhl Jena, Germany, Sept. 21, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the… |
| 20 Aug 2026 | Yahoo Finance |
InflaRx Announces Participation in September Investor Conferences
Jena, Germany, Aug. 20, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate in two investor conferences in September 2026. Details are as follows: Cantor… |
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |